Almost one year after filing a New Drug Application for an ADHD drug and less than one year after announcing it secured $200 million in financing, Ironshore Pharmaceuticals closed its doors.
Mr. du Toit is responsible for leading Publicis Health’s global business development strategy.
Novartis hired Elizabeth Barrett, Pfizer’s head of oncology, to replace Bruno Strigini, the chief executive officer of Novartis Oncology who retired at the end of 2017.
McCann Health announced the appointment of Marcus Sigurdsson to the new position of Global Chief Digital Officer.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to overhaul the company’s pharmaceutical division. Since assuming GSK’s helm, Walmsley has replaced about 50 of its top managers.
OvaScience is restructuring to cut costs. As part of that process, the company is laying off about half of its staff.
Expansion Therapeutics officially launched with the close of a $55.3 million Series A financing.
Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, announced the promotion of five employees in its Chicago office.
Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.
Intouch Solutions Advances Strategic Planning and Client Services Offerings with Leadership Promotions
Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, announced several leadership promotions.
Diane Iler-Smith has returned to Biolumina as SVP, Executive Creative Director. Biolumina is a full-service, integrated agency delivering omnichannel solutions for the pharmaceutical industry
Share prices for Protalix Biotherapeutics were up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease. Despite that positive news on its pipeline, Protalix is reportedly set to terminate 50 employees, which amounts to about 20 percent of its workforce.
Teva Pharmaceutical Industries announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation.
Ardelyx decided to shutter development of RDX7675 – an experimental medicine for hyperkalemia – including the onset-of-action trial and Phase III studies.
CRO giant Pharmaceutical Product Development LLC terminated a number of employees in its human resources department, but has provided few details about the job cuts, according to reports.
W2O Group, a network of innovative analytics-driven, digital-first marketing and communications firms, announced the appointment of three senior executives in its growing Chicago office.
GlaxoSmithKline poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head.
Omnicom Health Group announced that Mario Muredda has been named CEO of Harrison and Star and former CEO Ty Curran has been promoted to chairman. The changes are effective January 1, 2018.
Omnicom Health Group announced that Kirsten A. Kantak was appointed CEO of Biolumina.
X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.